文献速递头颈外科小儿耳鼻咽喉

儿童头颈部脊索瘤的预后因素与生存结局:基于SEER数据库的国家级分析

Pediatric Head and Neck Chordomas: A National Analysis of Prognostic Indicators and Survival Outcomes.
PubMed 文献 · Otolaryngol Head Neck Surg · 2025-11-18

该横断面分析利用SEER 22数据库(2000–2021年)纳入141例<19岁头颈部脊索瘤患者,评估人口学与临床病理特征对总生存(OS)和癌症特异性生存(CSS)的影响。多数肿瘤为经典型(85.8%)且位于颅底(84.4%);年龄≥10岁与更好的OS和CSS相关,去分化和软骨样亚型分别与更差的CSS相关,根治性化疗为OS和CSS的不良风险因素。

要点

  • 儿童头颈部脊索瘤多位于颅底,经典型占85.8%。
  • 年龄≥10岁与更好的OS和CSS独立相关。
  • 去分化/软骨样亚型及根治性化疗与更差生存相关。

核心结论

  • 儿童头颈部脊索瘤主要发生于颅底,生存结局受年龄、肿瘤组织学和治疗方式影响。
  • 较小年龄、非经典型组织学和化疗与更差预后相关,强调年龄适配的多学科管理策略的重要性。

研究设计与样本

  • 横断面分析,基于美国国家癌症研究所SEER 22数据库,纳入2000至2021年<19岁头颈部脊索瘤患者141例。
  • 采用描述性统计并按年龄(<10岁 vs ≥10岁)分层,Kaplan-Meier法估计OS和CSS,Cox比例风险模型评估生存相关因素。

主要发现

  • 141例中57.4%年龄≥10岁;年龄≥10岁与更好的OS和CSS相关(调整后HR分别为0.26和0.14)。
  • 大多数肿瘤为经典型脊索瘤(85.8%),位于颅底者占84.4%。
  • 去分化和软骨样亚型分别更常见于<10岁和≥10岁患者,两者均与显著更差的CSS相关(调整后HR分别为8.06和6.36)。
  • 诊断时41.8%为局限性疾病,9.9%有远处转移;最常见治疗为手术联合辅助放疗(40.7%)。
  • 根治性化疗是更差OS(HR 8.99)和CSS(HR 11.67)的风险因素。

临床怎么用

  • 对儿童头颈部脊索瘤应结合年龄、组织学亚型和治疗方式评估预后。
  • 年龄<10岁、非经典型组织学或接受化疗者预后更差,需考虑年龄适配的多学科管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To identify prognostic factors among pediatric patients with head and neck chordomas. STUDY DESIGN: Cross-sectional analysis. SETTING: The National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) 22 database. METHODS: Pediatric patients (<19 years of age) with head and neck chordomas were identified using the SEER database, spanning the years 2000 through 2021. Demographics and clinicopathologic characteristics were assessed using descriptive statistics and stratified by age (<10 years vs ≥10 years). Overall survival (OS) and cancer-specific survival (CSS) were estimated using Kaplan-Meier analysis, and Cox proportional hazards models were used to evaluate the associations with survival. RESULTS: Among the 141 cases, 57.4% were aged ≥10 years. Age ≥10 years was associated with improved OS and CSS (adjusted HRs 0.26 and 0.14, respectively) Most tumors were conventional chordomas (85.8%) located in the skull base (84.4%). Dedifferentiated and chondroid subtypes were more common in patients <10 and ≥10 years, respectively, and both were associated with significantly worse CSS (adjusted HRs 8.06 and 6.36, respectively). At diagnosis, 41.8% had localized disease, while 9.9% had distant metastases. The most common treatment was surgery with adjuvant radiation (40.7%). Definitive chemotherapy was a risk factor for worse OS (HR 8.99) and CSS (HR 11.67). CONCLUSION: Pediatric head and neck chordomas primarily develop at the skull base, with survival outcomes influenced by factors such as age, tumor histology, and treatment approach. Younger age, nonconventional histology, and chemotherapy were associated with poorer prognosis, highlighting the importance of age-appropriate, multidisciplinary management strategies.

来源:Otolaryngol Head Neck Surg,查看原文。版权归原作者所有。

引用

  1. Clementi EA, Timothee P, Charles-Obi K, et al. Pediatric Head and Neck Chordomas: A National Analysis of Prognostic Indicators and Survival Outcomes. Otolaryngol Head Neck Surg. 2025. PMID: 41252601. doi:10.1002/ohn.70066

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。